While its oncogenic role has been reviewed previously [10], recent research continues to explore TRA2β’s specific therapeutic potential in ovarian cancer [23], squamous cell carcinoma [38,39,40], and colon adenocarcinoma [41]. This evidence concerns the gene TRA2B and squamous cell carcinoma.